Literature DB >> 8247055

The natural history of borderline isolated systolic hypertension.

A Sagie1, M G Larson, D Levy.   

Abstract

BACKGROUND: Patients with isolated systolic hypertension are at increased risk for cardiovascular disorders. We attempted to determine whether those with borderline isolated systolic hypertension (defined as a systolic blood pressure of 140 to 159 mm Hg and a diastolic blood pressure below 90 mm Hg) have a greater risk of progression to definite (more severe) hypertension and of major morbid or fatal events than people with normal blood pressure (< 140/90 mm Hg).
METHODS: A total of 2767 of the original participants in the Framingham Heart Study were monitored with biennial examinations for up to 34 years for the development of definite hypertension (defined as a systolic blood pressure of > or = 160 mm Hg, a diastolic blood pressure of > or = 90 mm Hg, or the initiation of antihypertensive therapy) and for major cardiovascular events.
RESULTS: Borderline isolated systolic hypertension was the most common type of untreated hypertension among adults over the age of 60. After 20 years of follow-up, 80 percent of those with borderline isolated systolic hypertension had progression to definite hypertension, as compared with 45 percent of the normotensive participants (P < 0.001). After adjustment for age, sex, and risk factors for cardiovascular disease, participants with borderline isolated systolic hypertension had an excess long-term risk of cardiovascular disease (hazard ratio, 1.47; 95 percent confidence interval, 1.24 to 1.74) and death from cardiovascular disease (hazard ratio, 1.57; 95 percent confidence interval, 1.24 to 2.00), as compared with normotensive participants. In an analysis of pooled data from biennial examinations to study short-term sequelae, subjects with borderline isolated systolic hypertension had an increased risk of progression to definite hypertension (odds ratio, 3.84; 95 percent confidence interval, 3.35 to 4.41) and of cardiovascular disease (odds ratio, 1.39; 95 percent confidence interval, 1.06 to 1.82).
CONCLUSIONS: In both the short term and the long term, subjects with borderline isolated systolic hypertension are at increased risk of progression to definite hypertension and the development of cardiovascular disease.

Entities:  

Mesh:

Year:  1993        PMID: 8247055     DOI: 10.1056/NEJM199312233292602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  42 in total

Review 1.  Systolic hypertension and cardiovascular risk reduction: a clinical review.

Authors:  W C Cushman
Journal:  Curr Hypertens Rep       Date:  2001-09       Impact factor: 5.369

Review 2.  Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?

Authors:  S S Franklin
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

3.  Lifestyle changes to prevent and control hypertension: do they work? A summary of the Canadian consensus conference.

Authors:  N R Campbell; E Burgess; G Taylor; E Wilson; J Cléroux; J G Fodor; L Leiter; J D Spence
Journal:  CMAJ       Date:  1999-05-04       Impact factor: 8.262

4.  Association between medication adherence and clinical outcomes in patients with chronic kidney disease: a prospective cohort study.

Authors:  Mayuree Tangkiatkumjai; Dawn-Marie Walker; Kearkiat Praditpornsilpa; Helen Boardman
Journal:  Clin Exp Nephrol       Date:  2016-07-20       Impact factor: 2.801

5.  Facts and principles learned at the 31st Annual Williamsburg Conference on Heart Disease.

Authors:  Mark A Peterman; Hassan Farooq; William C Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-04

6.  Facts and principles learned at the 32nd annual Williamsburg Conference on Heart Disease.

Authors:  William Clifford Roberts; Hassan Farooq
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-04

7.  Hypertension subtype and risk of cardiovascular disease in Chinese adults.

Authors:  Tanika N Kelly; Dongfeng Gu; Jing Chen; Jian-feng Huang; Ji-chun Chen; Xiufang Duan; Xigui Wu; C Lillian Yau; Paul K Whelton; Jiang He
Journal:  Circulation       Date:  2008-09-22       Impact factor: 29.690

Review 8.  Hypertension, hypertrophy, heart failure.

Authors:  M G Nicholls
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

9.  Health system factors and antihypertensive adherence in a racially and ethnically diverse cohort of new users.

Authors:  Alyce S Adams; Connie Uratsu; Wendy Dyer; David Magid; Patrick O'Connor; Arne Beck; Melissa Butler; P Michael Ho; Julie A Schmittdiel
Journal:  JAMA Intern Med       Date:  2013-01-14       Impact factor: 21.873

10.  Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study.

Authors:  O James Ekundayo; Richard M Allman; Paul W Sanders; Inmaculada Aban; Thomas E Love; Donna Arnett; Ali Ahmed
Journal:  Hypertension       Date:  2009-02-02       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.